Cystitis Pipeline: 15+ Innovators Advancing Disease-Modifying and Symptomatic Therapies | DelveInsight

Cystitis, an inflammation of the bladder often caused by bacterial infection, has drawn significant attention from over 15 key companies, including Seikagaku Corporation, Lipella Pharmaceuticals, AlloVir, Ironwood Pharmaceuticals, and Paratek Pharmaceuticals. The cystitis pipeline includes therapies targeting bacterial infections, bladder pain relief, and improving urinary tract health. This pipeline features both disease-modifying treatments aiming to prevent recurrent infections and symptomatic therapies to alleviate pain, urgency, and discomfort associated with cystitis. With a growing focus on targeting bacterial resistance and improving patient quality of life, this pipeline represents an essential area of development in urinary tract health.

DelveInsight's "Cystitis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the cystitis market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging cystitis drugs, the cystitis pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Explore the full pipeline analysis for cystitis and uncover key opportunities @ https://www.delveinsight.com/report-store/cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cystitis Pipeline Report
• DelveInsight's cystitis pipeline analysis depicts a strong space with 15+ active players working to develop 15+ pipeline drugs for cystitis treatment.
• The leading cystitis companies include Seikagaku Corporation, Lipella Pharmaceuticals, AlloVir, Ironwood Pharmaceuticals, Paratek Pharmaceuticals, Alivio Therapeutics, Vaneltix Pharma, Qu Biologics, Imbrium Therapeutics, MIRAE CELL BIO, and others are evaluating their lead assets to improve the cystitis treatment landscape.
• Key cystitis pipeline therapies in various stages of development include SI 722, Tacrolimus liposomal, Posoleucel, IW-3300, Omadacycline, IMB 150, VNX 002, QBECP, Sunobinop, MR-MC-01, and others.
• In October 2024, Iterum Therapeutics announced that the FDA approved its oral antibiotic, ORLYNVAH, for treating uncomplicated urinary tract infections (UTIs) in adult women who have limited oral antibacterial treatment options. The approval follows successful late-stage trials showing the drug's safety and efficacy. Orlynvah is expected to be commercially available by mid-2025. ​
• In June 2024, Orchid Pharma announced the launch of its new drug, Cefepime-Enmetazobactam, for treating complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). The company has partnered with Cipla Ltd for the distribution of this drug, which aims to address antimicrobial resistance by targeting resistant bacterial strains. ​

Request a sample and discover the recent breakthroughs happening in the cystitis pipeline landscape @ https://www.delveinsight.com/report-store/cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cystitis Overview
Cystitis is an infection of the urinary bladder, categorized into uncomplicated and complicated forms. Uncomplicated cystitis typically affects healthy individuals, especially non-pregnant women, while complicated cystitis involves risk factors that make the infection more difficult to treat. The most common cause of cystitis is a bacterial infection, primarily Escherichia coli (E. coli), which colonizes the bladder from the periurethral mucosa.

Symptoms include painful urination, frequent urination, urgency, and sometimes suprapubic pain. These symptoms can also indicate other conditions like bladder cancer or urethral issues. Diagnosis involves urine tests and may include cystoscopy or imaging to rule out other causes.

Treatment typically involves antibiotics, and for chronic interstitial cystitis, medications target the underlying cause. Surgery is considered when other treatments fail. While treatable, cystitis can be more complex in complicated cases, requiring specialized care.

Find out more about cystitis medication @ https://www.delveinsight.com/report-store/cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cystitis Treatment Analysis: Drug Profile
SI-722: Seikagaku Corporation
SI-722 is an innovative chemical compound where a steroid is conjugated with chondroitin sulfate through Seikagaku's proprietary glycosaminoglycan modification technology and drug delivery systems. Although the Phase I/II clinical trial in the U.S. faced delays due to COVID-19, subject enrollment was completed in January 2021, and tolerability was confirmed. Seikagaku Corporation is now moving forward with the next phase of trials based on the collected data.

Tacrolimus Liposomal: Lipella Pharmaceuticals
Lipella Pharmaceuticals' lead product, LP-10, is designed for the treatment of hemorrhagic cystitis and is currently undergoing a Phase II multi-center clinical trial. Lipella has also received U.S. FDA Orphan Drug Designation for this product.

Posoleucel: AlloVir
Posoleucel is designed to provide critical bridging immunity during the period between conditioning and immune system reconstitution. By restoring immunity during severe immune compromise, posoleucel may significantly reduce or prevent virus-associated morbidity and mortality, improving patient outcomes. The drug is currently in Phase II development for treating hemorrhagic cystitis.

Learn more about the novel and emerging cystitis pipeline therapies @ https://www.delveinsight.com/report-store/cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cystitis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Cystitis Pipeline Report
• Coverage: Global
• Key Cystitis Companies: Seikagaku Corporation, Lipella Pharmaceuticals, AlloVir, Ironwood Pharmaceuticals, Paratek Pharmaceuticals, Alivio Therapeutics, Vaneltix Pharma, Qu Biologics, Imbrium Therapeutics, MIRAE CELL BIO, and others.
• Key Cystitis Pipeline Therapies: SI 722, Tacrolimus liposomal, Posoleucel, IW-3300, Omadacycline, IMB 150, VNX 002, QBECP, Sunobinop, MR-MC-01, and others.

Dive deep into rich insights for drugs used for cystitis treatment; visit @ https://www.delveinsight.com/report-store/cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cystitis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cystitis Pipeline Therapeutics
6. Cystitis Pipeline: Late-Stage Products (Phase III)
7. Cystitis Pipeline: Mid-Stage Products (Phase II)
8. Cystitis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.